Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 22Terminated 4Withdrawn 2Unknown 1Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 11Neoplasm Metastasis 2HER2 Positive Metastatic Breast Cancer 2Urinary Bladder Neoplasms 1Oesophagogastric Cancer 1Neoplasms 1Invasive Breast Cancer 1HER2-positive Advanced Breast Cancer 1Gastrointestinal Neoplasms 1Gallbladder Neoplasms 1Endometrial Neoplasms 1Colorectal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Breast Diseases 1

Interventions

Exercise 19Drug Therapy 18pembrolizumab 13Capecitabine 11Blood Specimen Collection 11Surveys and Questionnaires 10Radiotherapy 10Paclitaxel 9Dexamethasone 9Nivolumab 8Standard of Care 7Oxaliplatin 7Fluorouracil 7Erlotinib Hydrochloride 7apatinib 6Interviews as Topic 6Gemcitabine 6Control Groups 6Cisplatin 6Therapeutics 5Neoadjuvant Therapy 5Mindfulness-Based Cognitive Therapy 5Metformin 5Injections 5Everolimus 5Docetaxel 5Cyclophosphamide 5Bevacizumab 5sintilimab 4atezolizumab 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Neoplasms × Lapatinib × Clear all
NCT01283789 2017-02-08

Lapatinib and RAD-001 for HER2 Positive Metastatic Breast Cancer

University of Kansas Medical Center

Phase 2 Unknown
23 enrolled
Breast

Breast Neoplasms, Neoplasm Metastasis, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡